Biothorpe Pharmaceuticals

Biothorpe Pharmaceuticals was a biotechnology company founded in 2008 as a subsidiary of ZaBeCor Pharmaceuticals. Based in Bala Cynwyd, Pennsylvania, the company specialized in developing siRNA, antisense, and other molecular technologies for oncology applications. Its primary focus was targeting Spleen tyrosine kinase (Syk), a protein critical for the survival and proliferation of malignant cells in various hematologic cancers. The company's pipeline included pre-clinical programs such as Rebelex for acute myeloid leukemia, Lymphozene for B-cell lymphoma, and Leukozene for chronic lymphocytic leukemia. Biothorpe's intellectual property was derived from research conducted at the University of Pennsylvania School of Medicine. The company is currently inactive and considered out of business.